Natera, Inc. (NTRA) Downgraded to “Strong Sell” at ValuEngine

Natera, Inc. (NASDAQ:NTRA) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a report issued on Monday, July 24th.

A number of other research firms also recently commented on NTRA. Zacks Investment Research downgraded Natera from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Canaccord Genuity lifted their target price on Natera from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Wednesday, May 10th. Four research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $14.45.

Shares of Natera (NASDAQ NTRA) opened at 11.19 on Monday. The company’s market cap is $595.57 million. The stock’s 50 day moving average is $9.95 and its 200-day moving average is $9.62. Natera has a one year low of $7.35 and a one year high of $12.95.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Tuesday, August 8th. The medical research company reported ($0.52) earnings per share for the quarter, hitting the consensus estimate of ($0.52). The business had revenue of $53.60 million during the quarter, compared to the consensus estimate of $50.57 million. Natera had a negative return on equity of 137.46% and a negative net margin of 62.64%. The company’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.46) earnings per share. Equities research analysts expect that Natera will post ($2.03) earnings per share for the current year.

WARNING: This article was first posted by BNB Daily and is the property of of BNB Daily. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.baseball-news-blog.com/2017/08/19/valuengine-downgrades-natera-inc-ntra-to-strong-sell-updated-updated-updated.html.

Several hedge funds have recently bought and sold shares of the stock. GSA Capital Partners LLP acquired a new stake in Natera during the fourth quarter worth approximately $121,000. Virtu KCG Holdings LLC acquired a new stake in Natera during the second quarter worth approximately $126,000. Russell Investments Group Ltd. acquired a new stake in Natera during the fourth quarter worth approximately $130,000. American International Group Inc. boosted its stake in Natera by 7.1% in the first quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock worth $142,000 after buying an additional 1,068 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Natera by 1.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 16,118 shares of the medical research company’s stock valued at $143,000 after buying an additional 194 shares during the last quarter. Institutional investors and hedge funds own 59.86% of the company’s stock.

About Natera

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply